15th ISCT Annual Meeting

第15届ISCT年会

基本信息

项目摘要

DESCRIPTION (provided by applicant): The ISCT annual meeting is the premier opportunity for those working or interested in cell based therapeutic development to exchange scientific, clinical, technical, commercial, and regulatory information with colleagues from academia, industry, and regulatory agencies around the world. Last year's conference welcomed over 660 delegates from all over the world. We expect a modest increase again this year and are planning to host over 700 people. To enhance our program, we are adding an interactive Public Session aimed at encouraging high school and college students to pursue careers as researchers and physicians in the area of cellular therapy. The chairs of this meeting are Dr. Steven Forman, Clinical Director, Division of Cancer Immunotherapeutics and Tumor Immunology, City of Hope and Dr. Bruce Torbett, Associate Professor, Department of Molecular and Experimental Medicine, Scripps Research Institute. Program Objectives The objectives of the ISCT annual meeting include: (a) emphasizing the translational aspects of and issues involved with all types of cell and tissue-based research (b) Encouraging cross-disciplinary participation in Society activities (e.g., membership, publications, educational programs, conferences, etc) from scientists, clinicians, laboratory personnel, regulatory professionals, and others from both academia and industry (c) Addressing the scientific, clinical, laboratory and regulatory issues related to each type of cell-based research/therapy (d) facilitating the translation of information and experience from more mature cellular research areas such as hematopoietic stem cell transplantation to other emerging areas including nonhematopoietic areas such as mesenchymal stem cells, islet cells, etc and (d) Facilitating the transfer of information and experience from senior practicioners to young scientists in the field. (End of Abstract)
描述(由申请人提供): ISCT年会是那些工作或对基于细胞的治疗开发感兴趣的人与来自世界各地的学术界,工业界和监管机构的同事交流科学,临床,技术,商业和监管信息的首要机会。去年的会议欢迎来自世界各地的660多名代表。 我们预计今年将再次适度增加,并计划接待700多人。为了加强我们的计划,我们增加了一个互动的公共会议,旨在鼓励高中和大学生追求事业作为研究人员和医生在细胞治疗领域。 本次会议的主席是希望之城癌症免疫治疗和肿瘤免疫学部临床主任Steven Forman博士和Scripps研究所分子和实验医学系副教授布鲁斯Torbett博士。 计划目标 ISCT年会的目标包括:(a)强调所有类型的细胞和组织研究的转化方面和问题 (b)鼓励跨学科参与社会活动(例如,成员资格、出版物、教育计划、会议等),来自科学家、临床医生、实验室人员、监管专业人员以及来自学术界和工业界的其他人员 (c)解决与每种类型的基于细胞的研究/治疗相关的科学、临床、实验室和监管问题 (d)促进信息和经验从更成熟的细胞研究领域如造血干细胞移植到其他新兴领域,包括非造血领域如间充质干细胞、胰岛细胞等的转化, (d)促进资深科研人员向该领域的年轻科学家传授信息和经验。 (End摘要)

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stephen J Forman其他文献

Development and optimization of PSCA-specific CAR T cells for the treatment of bone metastatic prostate cancer
  • DOI:
    10.1186/2051-1426-3-s2-p115
  • 发表时间:
    2015-11-04
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Ethan Gerdts;Saul Priceman;Dileshni Tilakawardane;Anthony Park;Wen-Chung Chang;Sarah Wright;Christine E Brown;Stephen J Forman
  • 通讯作者:
    Stephen J Forman
Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma
  • DOI:
    10.1182/blood-2022-167626
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Matthew Mei;Joycelynne Palmer;Ni-Chun Tsai;Hun Ju Lee;Iris Isufi;Leslie L. Popplewell;Lynne Smith;Lacolle Peters;Lara Rodriguez;James Godfrey;John H. Baird;Joo Y. Song;Steven T. Rosen;Larry W. Kwak;Stephen J Forman;Alex F. Herrera
  • 通讯作者:
    Alex F. Herrera
Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
  • DOI:
    10.1182/blood-2022-169964
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Amandeep Salhotra;Nelli Bejanyan;Dongyun Yang;Sally Mokhtari;Monzr M. Al Malki;Karamjeet S. Sandhu;Rawan Faramand;Ibrahim Aldoss;Andrew S. Artz;Ahmed Aribi;Hany Elmariah;Firoozeh Sahebi;Joshua Mansour;Brian J Ball;Vaibhav Agrawal;Ling Li;Vinod A. Pullarkat;Stephen J Forman;Guido Marcucci;Ryotaro Nakamura
  • 通讯作者:
    Ryotaro Nakamura
Positive Coombs Test in Hodgkin's Disease: Significance and Implications
  • DOI:
    10.1182/blood.v55.4.607.607
  • 发表时间:
    1980-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Alexandra M Levine;Phyllis Thornton;Stephen J Forman;Philip Van Hale;Diane Holdorf;Charles L Rouault;Darlene Powars;Donald I Feinstein;Robert J Lukes
  • 通讯作者:
    Robert J Lukes
Development of chimeric antigen receptor (CAR) T-cell immunotherapy for glioblastoma targeting epidermal growth factor receptor variant III (EGFRvIII)
  • DOI:
    10.1186/2051-1426-3-s2-p119
  • 发表时间:
    2015-11-04
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Anthony K Park;Saul Priceman;Ethan Gerdts;Wen-Chung Chang;Sarah Wright;Stephen J Forman;Christine E Brown
  • 通讯作者:
    Christine E Brown

Stephen J Forman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stephen J Forman', 18)}}的其他基金

Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma
脑室内 (ICV) 施用靶向 CD19 的嵌合抗原受体 (CAR) T 细胞治疗原发性中枢神经系统淋巴瘤
  • 批准号:
    10522948
  • 财政年份:
    2022
  • 资助金额:
    $ 0.8万
  • 项目类别:
Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma
脑室内 (ICV) 施用靶向 CD19 的嵌合抗原受体 (CAR) T 细胞治疗原发性中枢神经系统淋巴瘤
  • 批准号:
    10700973
  • 财政年份:
    2022
  • 资助金额:
    $ 0.8万
  • 项目类别:
Transfer of COVID-19 Immunity Between
COVID-19 免疫力的转移
  • 批准号:
    10268483
  • 财政年份:
    2020
  • 资助金额:
    $ 0.8万
  • 项目类别:
Image-guided irradiation safely intensifies HSCT regimen for refractory leukemia
图像引导照射安全强化难治性白血病的 HSCT 治疗方案
  • 批准号:
    9011868
  • 财政年份:
    2015
  • 资助金额:
    $ 0.8万
  • 项目类别:
Radioimmunotherapy Based Transplant Regimens for Treatment of B-Cell Lymphoma and
基于放射免疫疗法的 B 细胞淋巴瘤和移植治疗方案
  • 批准号:
    7016807
  • 财政年份:
    2006
  • 资助金额:
    $ 0.8万
  • 项目类别:
Administration/Regulatory Affairs
行政/监管事务
  • 批准号:
    7016811
  • 财政年份:
    2006
  • 资助金额:
    $ 0.8万
  • 项目类别:
City of Hope Lymphoma SPORE
希望之城淋巴瘤孢子
  • 批准号:
    7932588
  • 财政年份:
    2004
  • 资助金额:
    $ 0.8万
  • 项目类别:
CMV/CD19 bi-Specific CAR T cells combined with CMV vaccine as post-transplantation immunotherapy for non-Hodgkin lymphoma
CMV/CD19双特异性CAR T细胞联合CMV疫苗作为非霍奇金淋巴瘤移植后免疫治疗
  • 批准号:
    10242159
  • 财政年份:
    2004
  • 资助金额:
    $ 0.8万
  • 项目类别:
CMV/CD19 bi-Specific CAR T cells combined with CMV vaccine as post-transplantation immunotherapy for non-Hodgkin lymphoma
CMV/CD19双特异性CAR T细胞联合CMV疫苗作为非霍奇金淋巴瘤移植后免疫治疗
  • 批准号:
    10456960
  • 财政年份:
    2004
  • 资助金额:
    $ 0.8万
  • 项目类别:
City of Hope Lymphoma SPORE
希望之城淋巴瘤孢子
  • 批准号:
    7124751
  • 财政年份:
    2004
  • 资助金额:
    $ 0.8万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 0.8万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 0.8万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.8万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.8万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 0.8万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.8万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 0.8万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 0.8万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 0.8万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.8万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了